Fact CheckerSign in

NCT07250750RecruitingPhase 1/2

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants With Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

Source: ClinicalTrials.gov · Last updated 11 Feb 2026

Brief summary (registry, in English)

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG.

Status (registry)
Recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
96 (estimated)
First submitted
26 Oct 2025
Start date
5 Feb 2026
Primary completion date
Dec 2027
Lead sponsor
ImmunAbs Inc.
NCT number
NCT07250750
EU CT number
2025-522406-20-00

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 96
  • From 5 Feb 2026 to the primary completion date, Dec 2027
  • 26 sites in 6 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous exposure to IM-101
  • Anti-MuSK antibody Positive
  • Has been treated with any complement inhibitor, but failed due to intolerability or lack of efficacy
    • Full eligibility criteria is available in the study protocol.

Other illness

  • History of malignant thymoma, or history of cancer within the past 5 years of screening
  • History of N. meningitidis infection

Who the study is looking for

  • Able and willing to provide signed informed consent
  • Willingness to consent to screening for genetic muscular diseases
  • Male or female aged ≥ 18 years and \< 75 years
  • Diagnosed with MG
  • On a stable dose of background therapy for the treatment of MG
  • Body weight ≥ 40 kg at screening
  • Vaccinated against meningococcal infection (Neisseria meningitidis), streptococcus pneumoniae, and haemophilus influenzae type B

Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (26)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Medical Center Hera EOOD
Coordinator of this site? Confirm its status
MontanaBulgariaRecruiting
University Multiprofile Hospital for Active Treatment Dr Georgi Stranski EAD
Coordinator of this site? Confirm its status
PlevenBulgariaRecruiting
Multiprofile Hospital For Active Treatment Avis Medika OOD
Coordinator of this site? Confirm its status
PlevenBulgariaRecruiting
Medical Center Neurocentrum EOOD
Coordinator of this site? Confirm its status
PlovdivBulgariaRecruiting
Uniteversity Muliprofile Hospital For Active Treatment Tsaritsa Yoanna-Isul EAD
Coordinator of this site? Confirm its status
SofiaBulgariaRecruiting
Haelan Care 4 Medical Center Ltd.
Coordinator of this site? Confirm its status
VarnaBulgariaRecruiting
Hospital Clínico San Carlos
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario La Paz
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario Central De Asturias
Coordinator of this site? Confirm its status
OviedoSpainRecruiting
Clínica Universidad de navarra
Coordinator of this site? Confirm its status
PamplonaSpainRecruiting
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Coordinator of this site? Confirm its status
BresciaItalyRecruiting
IRCCS Foundation Istituto Neurologico Carlo Besta
Coordinator of this site? Confirm its status
MilanItalyRecruiting
Ospedale San Raffaele S.r.l.
Coordinator of this site? Confirm its status
MilanItalyRecruiting
Neurologia Śląska Centrum Medyczne
Coordinator of this site? Confirm its status
KatowicePolandRecruiting
Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.
Coordinator of this site? Confirm its status
Nowa SolPolandRecruiting
Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.
Coordinator of this site? Confirm its status
PoznanPolandRecruiting
Ilkowski I Partnerzy sp.p. Lekarzy
Coordinator of this site? Confirm its status
PoznanPolandRecruiting
General Hospital MSB Medical System Belgrade
Coordinator of this site? Confirm its status
BelgradeSerbiaNot yet recruiting
Neurology of Central Florida Research Center LLC
Coordinator of this site? Confirm its status
Altamonte SpringsUnited StatesRecruiting
SFM Clinical Research LLC
Coordinator of this site? Confirm its status
Boca RatonUnited StatesRecruiting
Houston Methodist Neurological Institute
Coordinator of this site? Confirm its status
HoustonUnited StatesNot yet recruiting
Nerve & Muscle Center of Texas
Coordinator of this site? Confirm its status
HoustonUnited StatesRecruiting
University of Kansas Medical Center Research Institute, Inc
Coordinator of this site? Confirm its status
Kansas CityUnited StatesNot yet recruiting
Aqualane Clinical Research
Coordinator of this site? Confirm its status
NaplesUnited StatesRecruiting
Medsol Clinical Research Center
Coordinator of this site? Confirm its status
Port CharlotteUnited StatesNot yet recruiting
University of South Florida
Coordinator of this site? Confirm its status
TampaUnited StatesNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.